Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
ABBV-400 by AbbVie for Uterine Cancer: Likelihood of Approval
ABBV-400 is under clinical development by AbbVie and currently in Phase I for Uterine Cancer. According to GlobalData, Phase I...
ABBV-400 by AbbVie for Melanoma: Likelihood of Approval
ABBV-400 is under clinical development by AbbVie and currently in Phase I for Melanoma. According to GlobalData, Phase I drugs...
Lutikizumab by AbbVie for Hidradenitis Suppurativa: Likelihood of Approval
Lutikizumab is under clinical development by AbbVie and currently in Phase III for Hidradenitis Suppurativa. According to GlobalData, Phase III...
Venetoclax by AbbVie for Transformed Mycosis Fungoides: Likelihood of Approval
Venetoclax is under clinical development by AbbVie and currently in Phase II for Transformed Mycosis Fungoides. According to GlobalData, Phase...
Ibrutinib by AbbVie for Primary CNS Lymphoma: Likelihood of Approval
Ibrutinib is under clinical development by AbbVie and currently in Phase II for Primary CNS Lymphoma. According to GlobalData, Phase...
Venetoclax by AbbVie for Natural Killer Cell Lymphomas: Likelihood of Approval
Venetoclax is under clinical development by AbbVie and currently in Phase I for Natural Killer Cell Lymphomas. According to GlobalData,...
Venetoclax by AbbVie for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval
Venetoclax is under clinical development by AbbVie and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL). According to GlobalData,...
Venetoclax by AbbVie for Myeloproliferative Disorders: Likelihood of Approval
Venetoclax is under clinical development by AbbVie and currently in Phase II for Myeloproliferative Disorders. According to GlobalData, Phase II...
Venetoclax by AbbVie for Solid Tumor: Likelihood of Approval
Venetoclax is under clinical development by AbbVie and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
Venetoclax by AbbVie for Amyloidosis: Likelihood of Approval
Venetoclax is under clinical development by AbbVie and currently in Phase II for Amyloidosis. According to GlobalData, Phase II drugs...
Elsubrutinib by AbbVie for Systemic Lupus Erythematosus: Likelihood of Approval
Elsubrutinib is under clinical development by AbbVie and currently in Phase II for Systemic Lupus Erythematosus. According to GlobalData, Phase...
Telisotuzumab vedotin by AbbVie for Non-Small Cell Lung Cancer: Likelihood of Approval
Telisotuzumab vedotin is under clinical development by AbbVie and currently in Phase III for Non-Small Cell Lung Cancer. According to...
Serclutamab talirine by AbbVie for Glioblastoma Multiforme (GBM): Likelihood of Approval
Serclutamab talirine is under clinical development by AbbVie and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData,...
AGN-193408 SR by AbbVie for Ocular Hypertension: Likelihood of Approval
AGN-193408 SR is under clinical development by AbbVie and currently in Phase II for Ocular Hypertension. According to GlobalData, Phase...
AGN-193408 SR by AbbVie for Open-Angle Glaucoma: Likelihood of Approval
AGN-193408 SR is under clinical development by AbbVie and currently in Phase II for Open-Angle Glaucoma. According to GlobalData, Phase...
Budigalimab by AbbVie for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval
Budigalimab is under clinical development by AbbVie and currently in Phase II for Metastatic Adenocarcinoma of The Pancreas. According to...
Lemzoparlimab by AbbVie for Epithelial Ovarian Cancer: Likelihood of Approval
Lemzoparlimab is under clinical development by AbbVie and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData, Phase...
Risk adjusted net present value: What is the current valuation of AbbVie's Telisotuzumab Vedotin?
Telisotuzumab Vedotin is a monoclonal antibody conjugated commercialized by AbbVie, with a leading Phase III program in Non-Small Cell Lung...
Risk adjusted net present value: What is the current valuation of AbbVie's ABBV-668?
ABBV-668 is a small molecule commercialized by AbbVie, with a leading Phase II program in Ulcerative Colitis. According to Globaldata,...
Elsubrutinib by AbbVie for Systemic Lupus Erythematosus: Likelihood of Approval
Elsubrutinib is under clinical development by AbbVie and currently in Phase II for Systemic Lupus Erythematosus. According to GlobalData, Phase...